ROMIDEPSIN AND CARFILZOMIB IN RELAPSED / REFRACTORY PERIPHERAL T-CELL LYMPHOMA WITH ASSESSMENT OF H23B AS A PREDICTIVE BIOMARKER – THE UK NCRI SEAMLESS PHASE 1/2 ROMICAR TRIAL